|
Aficamten Approved, Most Favored Nation, and More Wins
January 5, 2026
|
|
|
|
|
Together with
|
|
|
|
Cardiology Pharmaceuticals
|
|
|
|
|
|
After years of dedicated research and careful science, Cytokinetics’ aficamten (Myqorzo) is officially FDA approved for obstructive hypertrophic cardiomyopathy, marking the company’s first-ever regulatory approval and ending BMS mavacamten’s reign as the only oHCM treatment.
- Aficamten is a reversible cardiac myosin inhibitor that reduces how hard the heart muscle can contract, which lowers left ventricular outflow tract (LVOT) obstruction.
The FDA’s decision stemmed from the SEQUOIA-HCM trial, which demonstrated aficamten’s efficacy over 24 weeks in symptomatic obstructive HCM patients and found that the drug led to significant benefits.
- Patients on aficamten saw a peak oxygen uptake increase of 1.8 mL/kg/min versus 0.0 mL/kg/min with placebo.
- Nearly 60% of aficamten patients showed improvement in physical activity abilities compared to 24% with placebo.
- The drug was well-tolerated with no cases of worsening HF and lower serious adverse events than placebo (5.6% vs. 9.3%).
Notably, even with these strong results, aficamten comes with the same Risk Evaluation and Mitigation Strategy (REMS) program requirement as mavacamten (e.g. echo monitoring), since both can increase HF risk due to systolic dysfunction.
- That’s because during the trial, LVEF of <50% occurred in 3.5% of aficamten patients versus 0.7% on placebo.
- As a result, aficamten also isn’t recommended for patients with a baseline LVEF of <55%.
- Hypertension (8% vs. 2%) represented the only adverse reaction that occurred in more than 5% of patients, which is common after LVOT obstruction relief.
So what’s the difference between aficamten and mavacamten and why is a second cardiac myosin inhibitor important?
- Aficamten binds away from the myosin’s action site, shifting the enzyme into a super-slow, low-energy state, which reduces how hard heart muscle can contract.
- Meanwhile, mavacamten binds to myosin’s action site, locking it in the “off” form and reducing the number of myosin molecules available for the heart muscle to use.
- Aficamten’s half-life is shorter (3-4 days), allowing for quicker dose changes, while mavacamten’s half-life is longer (6-9 days), requiring longer dose titration (months).
The Takeaway
Cytokinetics’ Fady Malik, MD, PhD, once said that “drug development is a challenging sport” but from the looks of it, aficamten has risen to the task of being the next, and potentially best oHCM drug available.
|
|
Explore Vitrea Advanced Visualization
Discover Canon Medical Healthcare IT’s suite of advanced imaging workflows designed to increase efficiency in cardiovascular imaging, and facilitate the assessment, diagnosis, and treatment of cardiovascular diseases. These cutting-edge tools support the delivery of faster, more accurate care while integrating seamlessly into clinical workflow
|
|
The Benefits of Outsourced Post-Processing
Using an outsourced cardiac image post-processing solution doesn’t have to mean sacrificing control of the results. Discover how PIA’s customizable post-processing workflow can help you get the most out of your images.
|
|
Heartflow Roadmap Analysis For Efficient Care
As Coronary CT scan volumes increase, your entire reading team needs to deliver efficient and consistent reads. Good thing Heartflow’s Roadmap Analysis can help you maintain accuracy and increase CCTA read speeds by up to 25%, with even level 3 readers seeing real efficiency benefits.
|
|
- Sapien M3 Approved for Transseptal TMVR: The FDA approved Edwards’ Sapien M3 system for transseptal transcatheter mitral valve replacement in patients with symptomatic mitral regurgitation who can’t have surgery or TEER. This makes Sapien M3 the first FDA-approved TMVR device delivered via a fully percutaneous approach across the heart’s septum, and adds to Edwards’ valve-in-valve and surgical MR offerings.
- Abbott’s Volt PFA Victory: Adding another option to the burgeoning pulse field ablation segment, the FDA approved Abbott’s Volt PFA System for treating AFib. The approval follows the VOLT-AF study, which demonstrated the Volt system’s safety and effectiveness for both paroxysmal and persistent AFib. Volt’s all-in-one design allows physicians to map, pace, and ablate with one catheter, integrating with Abbott’s EnSite X mapping system for improved workflow. The system enables conscious sedation instead of general anesthesia, delivers energy with fewer pulses, and reduces procedure times.
- The Art of the Pharma Deal: Nine of the world’s biggest pharmaceutical companies: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, GSK, Merck, Novartis, Genentech, and Sanofi, reached agreements with the Trump administration to lower certain drug prices in exchange for tariff relief (including some CV drugs). The “most favored nation” deals will match U.S. prices with the lowest prices in developed countries, offering discounts ranging from 60% to 90% on various medications. Drugs will be available through direct-to-patient programs, Medicaid, and the new TrumpRx.gov platform. AbbVie, Johnson & Johnson, and Regeneron are still in negotiations.
- Family Histories and LV Enlargement: Research from the Avon Longitudinal Study found that adolescents with family histories of cardiometabolic disease show severe increases in left ventricular enlargement prevalence. The study of 1.6k participants revealed that 30% of adolescents had family histories of hypertension, diabetes, or vascular disease, with LV enlargement rates rising from 2.4% at age 17 to 6.5% at age 24. Family history increased LV enlargement risk by 20%, with glucose levels explaining about 10% of this increased risk.
- Diabetes Remission Lowers CV Risk: A meta-analysis of U.S. and Chinese diabetes prevention studies found that achieving remission from prediabetes massively reduces a patient’s CV death or HF hospitalization risk. The pooled analysis of 3k patients showed those reaching remission had significantly lower event rates compared to non-remitters, with mortality and hospitalization risk decreasing by 53% over three decades. Only 11.5% achieved remission after one year, and fewer developed type 2 diabetes later.
- Andexxa Axed from U.S. Market: The FDA announced that AstraZeneca’s andexanet alfa (Andexxa), which reverses anticoagulation from rivaroxaban and apixaban, will no longer be available in the U.S. The agency determined that the risks of thromboembolic events outweigh benefits based on postmarketing data analysis and AstraZeneca voluntarily requested withdrawal for commercial reasons. Andexxa will still be available in Europe, the UK, Japan, and other markets under local regulations.
- LDL Levels Post-Stent: A post-hoc analysis of the CONNECT trial found that STEMI patients who achieved lower LDL cholesterol levels after stent implantation had significantly less neoatherosclerosis (atherosclerosis in the new tissue lining a stented artery) after 3 years. Per the study, each 25 mg/dL increase in LDL-C independently raised neoatherosclerosis odds by 46%. Researchers emphasize that aggressive lipid-lowering therapy (LDL below 55-70 mg/dL) is crucial for long-term stent health after the initial implantation.
- Oral Semaglutide Approved: Notching a big win, Novo Nordisk received FDA approval for its oral formulation of Wegovy (semaglutide) for weight management and cardiovascular risk reduction, making it the first oral GLP-1 approved for obesity treatment. The once-daily pill will launch in early January 2026 at $149 monthly for the 1.5 mg starting dose, up to a maximum 25 mg maintenance dose. Results from Novo’s Oasis-4 trial showed that patients achieved 16.6% average weight loss versus 2.7% with placebo, comparable to injectable Wegovy results.
- Ventric’s Vivio Validation Results: Ventric Health announced positive FDA validation study results that showed its Vivio System achieved 80% sensitivity and 83% specificity using left ventricular end-diastolic pressure calculated from a blood pressure cuff and ECG combo. The five-minute primary care test demonstrated six times greater sensitivity than echocardiography and twice the sensitivity of BNP blood tests. The FDA-approved system enables earlier heart failure detection before symptoms develop, potentially improving outcomes and reducing hospitalizations.
- Another New HCM Treatment: Edgewise Therapeutics reported positive interim safety results from the CIRRUS-HCM Phase 2 trial for its drug EDG-7500, an oral sarcomere modulator for HCM. The drug showed no clinically meaningful reductions in LVEF or drops below 50%, while demonstrating a favorable safety profile across doses from 25-150 mg. Over 40 participants enrolled in Part D of the study, with 70% reaching 100 mg or higher doses. The company is on track for full 12-week Part D results in Q2 2026 and Phase 3 initiation in Q4 2026.
- Sleep Apnea Test for AFib: Huxley Medical received additional FDA clearance for its SANSA home sleep apnea test that can now function as a diagnostic ECG monitor, making it the first home sleep test capable of detecting arrhythmias from a chest-worn patch. The 9-channel device combines sleep apnea testing with ECG assessment, addressing the gap created when testing shifted from lab polysomnography to home-based methods. This marks Huxley’s fourth FDA clearance in six quarters.
|
|
Us2.ai’s AI HF Now Possible with Handheld Echo
The latest research shows Us2.ai’s software can take handheld echocardiography beyond its standard applications. Read this EHJ study about how swiftly and accurately Us2.ai’s HF detection software detects LVEF, closely matching expert human analysis of standard cart based echocardiograms.
|
|
Streamline Your Cardiology Imaging Workflows
See how cardiologists and their teams can streamline imaging workflows to make their cardiovascular service line more efficient, cost-effective, and patient-centered, using Merge’s cardiology solutions.
|
|
- The Monebo Difference in Comprehensive Cardiac Mapping: Monitoring the heart 24/7 means being in tune with the body’s natural cycles. Read about how Monebo’s approach to cardiac monitoring provides visual representations of a patient’s heart rate, cardiac muscle relaxation, and electrical excitation throughout the day.
- Tempus Receives FDA 510(k) Clearance for Tempus ECG-Low EF: Tempus announces the expansion of its Tempus ECG-AI portfolio with Tempus ECG-Low EF, software intended for use to analyze 12-lead ECG recordings and detect signs associated with having a low left ventricular ejection fraction (LVEF less than or equal to 40%) in patients 40 years of age or older at risk of heart failure. It is not intended as a stand-alone diagnostic and positive results may suggest the need for further clinical evaluation. For Full Indications for Use, visit here.
- How Vista AI Helps Solve the Technologist Shortage: Fewer than 2% of MRI scanners are routinely used for cardiac imaging—mainly due to a shortage of trained technologists amid rising demand. Vista AI addresses this challenge by automating CMR scanning, empowering technologists of all experience levels to deliver high-quality cardiac exams consistently and efficiently.
- Siemens Healthineers ACUSON Origin Ultrasound System is Redefining CVUS: ACUSON Origin meets the demands of today’s cardiovascular care with AI-powered efficiency across adult and pediatric echo, vascular, structural heart, and EP. Streamlined workflows, intuitive walk-up usability, and advanced ergonomics empower clinicians to deliver confident, high-quality care—supporting a wide range of complex cases and clinical applications.
- What Every Cardiologist Needs to Watch for in Heart Failure: Patients with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) face a high risk of hospitalization for heart failure and cardiovascular death, even with guideline-directed medical treatment. Hear from Bayer’s Dr. Alanna Morris-Simon as she shares common heart failure signs to look out for.
|
|
|
|
|
